HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. - Test2 - elhamkhani - TriplyDB

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

http://www.wikidata.org/entity/Q36740297

about

Exploiting tumor epigenetics to improve oncolytic virotherapy Oncolytic viruses as therapeutic cancer vaccines HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases Oncolytic viruses as immunotherapy: progress and remaining challenges Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer HDAC inhibitors and immunotherapy; a double edged sword?Trial Watch:: Oncolytic viruses for cancer therapy Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes Trial Watch-Oncolytic viruses and cancer therapy Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy Integrating Transcriptomic and Proteomic Data Using Predictive Regulatory Network Models of Host Response to Pathogens.The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors Classification of current anticancer immunotherapies Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.First-in-class small molecule potentiators of cancer virotherapy.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta Maraba virus as a potent oncolytic vaccine vector.Oncolytic vaccines.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Oncolytic Immunotherapy for Treatment of Cancer.Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.

P2860

Q21131237-A6CBFFA7-2ECA-464B-886C-57D1C608EC87 Q21245758-5B45DCBA-A7C9-48D4-8AFC-33355EE10B74 Q26739120-63F78BF5-D2CD-44C4-A5E2-9A62D8206C35 Q26745942-EEB0D26C-8876-479B-A573-F57D29424CA3 Q26767209-38E2F849-AD3B-42F3-AFD9-3C8AF788EA84 Q26769977-9769C3C7-BBEC-469B-B1A3-5EFED99BBBF5 Q26822694-234FF6D9-3F91-4E3F-92D7-3119E88742FD Q26853102-C9BCB1C0-E80A-4D1A-86E3-FDC32D02F8F3 Q27021951-A32DFCA7-B1B3-42F1-AB67-8A8CFB012823 Q27324527-D3AE9730-D43A-4802-B30D-545F96487FCA Q28072347-0274DEB5-3F6A-4F3C-83D5-69F0DA0258F6 Q28083766-77091B97-B423-4BF7-9C07-0396E8DEF555 Q31114011-E9FFBC66-4296-4265-B7AE-8F880AAB1F59 Q33584049-20E5ECF5-6A7A-41DB-89B2-28F4F44D7B0F Q33732128-E1F7BB00-3379-49F1-842A-C7993E87F0E4 Q35149637-6E26EAC8-2C5A-4694-98FC-F59DF2749719 Q36664258-7D7B9BF8-EC69-41CD-A3E2-BCC561949243 Q36918248-CB72A988-7840-4313-9C4D-78ACA25E117B Q36937304-5BB9A9CE-B36A-41F6-BBDA-54B3ED5CA189 Q37078946-C2F1C934-3BD4-47BA-80EF-81392B193775 Q37196054-2BABED14-18C3-479E-81CD-16AE55DE2581 Q37477372-08EFD605-30C2-4DE1-935A-23D06CF646B0 Q37562080-91296F64-3B22-4DC8-91BF-F86D895BF2CE Q38152474-45B44F5D-84A1-4E26-89C6-2F124AC79994 Q38159802-C5A3D8C7-2F3C-4C2C-A550-3546828573C4 Q38223419-F299EB76-958B-436B-8083-AB819ACA5714 Q38237657-4E6D8C19-AB2F-4A94-BB48-2C382E32F8FD Q38240733-86364C0B-2FB5-4057-BAC6-68D625AFBBC0 Q38357137-2DD1901E-5015-427E-8B7A-49BDF551B2C9 Q38537768-6F9180D2-9CE4-49E4-B1C5-CF0720FB844F Q38641485-F4FBF762-206C-4F5F-8616-2CE63CA90F71 Q38710509-2BC04CB8-728E-4001-9CD3-D7EBD9D2A3DF Q38749824-FFB9CBB5-EB89-4221-B3FA-220147F0C719 Q38763747-14ADE43A-24F8-4909-8A29-C6B2DF395840 Q38838643-A7DA6F33-0B7B-4265-A868-E7463BED49B6 Q38845173-B8B017B5-4BCB-4D88-9FAA-37F9C8D57848 Q38845195-33766CD8-E7B6-49AB-8620-2FCB46B40F62 Q38848223-D35AD849-CA14-4E9C-995C-C8455AC6082D Q38924569-D95FBAB4-8D01-45E6-9CE4-B0F6C7C61E3D Q38948897-4BB0B520-5631-4010-A0C6-3E5AE1D94082

P2860

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

http://www.wikidata.org/entity/Q36740297

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@ast

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@en

type

label

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@ast

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@en

prefLabel

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@ast

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@en

P1433

Q36740297-58659A6B-555F-49AD-A7BC-8718A4DF354F

P1476

Q36740297-E0C13F36-256A-45A3-96C3-1DE8FF72A062

P2093

Q36740297-0BB21A08-0101-41F5-B43A-2E8E3477604E

Q36740297-0F1A74C3-0489-427B-B19F-A97BF659C0A4

Q36740297-304BED84-D005-4681-93B5-0EBC71F2057C

Q36740297-4121C6AC-4D48-4C00-9F86-F5346B2AC96B

Q36740297-4CA91E07-2413-4633-98B5-2579420B9DCB

Q36740297-86328CC6-9D4F-4C29-82F6-A5B210E77A9D

Q36740297-C98DD09F-F0AA-4BBB-96C3-5BF49A22F57B

Q36740297-FCE0F977-337F-4B7F-AB40-14E863F3BBA6

P2860

Q36740297-0E069161-CA9D-40AF-B49F-3E19BF32A01D

Q36740297-0E72D8D5-F9A0-44F2-B431-2B4A8DCA2668

Q36740297-10916F38-9638-4AC9-B448-DC21F78F2F1E

Q36740297-16789A3B-1CF7-49E4-AD17-D24AB84FF6EA

Q36740297-32F061CA-094D-4D21-A45E-805D5A2D7916

Q36740297-34E9D04E-07F1-48FF-8D10-79CFF873C351

Q36740297-398AE681-0995-45F9-B8C6-385D985770DC

Q36740297-4350739E-9018-490C-AEB3-484631B67BFF

Q36740297-45952045-362C-42D1-A151-8E4768C836D7

Q36740297-4920E19B-9BA7-444F-9258-739BBEEF4ADA

P304

Q36740297-CBC7F7BE-2F9D-4993-A1F3-008EB0B86C85

P31

Q36740297-47FF0121-4E75-4595-837A-C90697B8B7ED

P356

Q36740297-BF66A5D9-1DB1-4D60-A31C-25CE6EC1905C

P433

Q36740297-1B0EF200-E9E1-4A0A-8424-F835C2C536AD

P478

Q36740297-00392EFD-C22A-42F9-A101-B2FF5D2600F9

P50

Q36740297-239025BA-6A45-400F-83EB-C126DC19A89D

Q36740297-421F1577-1628-47BC-A5C5-AA8F18611E64

Q36740297-723C229D-56B6-46A2-94C1-50DB01FD8B52

Q36740297-D69A9239-78D4-4AD3-850B-6E47E8BB404E

P577

Q36740297-EF410FA5-303D-491D-9C45-BEDBCF8D18F9

P5875

Q36740297-D9A02C7D-363A-4826-91DD-CE235596006F

P698

Q36740297-74319754-4EBA-4D24-BB71-05A617E65390

P921

Q36740297-10E32CB9-F58B-47CF-8502-8E2061321181

P932

Q36740297-718F6D50-E570-4A44-A754-6B42667E2974

P356

P1433

Molecular Therapy

P1476

HDAC inhibition suppresses pri ...... ty during tumor immunotherapy.

@en

P2093

Alfredo Capretta

http://www.w3.org/2001/XMLSchema#string

Andrew Nguyen

http://www.w3.org/2001/XMLSchema#string

Brian D Lichty

http://www.w3.org/2001/XMLSchema#string

Byram W Bridle

http://www.w3.org/2001/XMLSchema#string

Chantal G Lemay

http://www.w3.org/2001/XMLSchema#string

Lan Chen

http://www.w3.org/2001/XMLSchema#string

Rongqiao He

http://www.w3.org/2001/XMLSchema#string

Yonghong Wan

http://www.w3.org/2001/XMLSchema#string

P2860

Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation.

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Potentiating cancer immunotherapy using an oncolytic virus

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

T-cell quality in memory and protection: implications for vaccine design

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.

P304

887-894

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.265

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Simon Diallo

Jonathan L Bramson

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234084099

http://www.w3.org/2001/XMLSchema#string

P698

23295947

http://www.w3.org/2001/XMLSchema#string

P921

P932

3616544

http://www.w3.org/2001/XMLSchema#string